{"filing":{"accession_number":"0001213900-26-074421","cik":"0001937993","ticker":"CVKD","company_name":"Cadrenal Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ea0296666-8k_cadrenal.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026074421/ea0296666-8k_cadrenal.htm"},"events":[{"id":15623,"run_id":13928,"accession_number":"0001213900-26-074421","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Cadrenal Therapeutics completed a private placement of 960,000 shares of common stock (or pre-funded warrants), Series C-1 and C-2 warrants, and placement agent warrants under Section 4(a)(2) and Regulation D exemptions, raising $3.0 million in gross proceeds at $3.1249 per unit, with up to $5.8 million in additional potential proceeds from warrant exercises. The unregistered securities extend the company's cash runway into Q1 2027 (or H2 2027 if warrants are exercised) and are subject to registration rights obligations.","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13471,"accession_number":"0001213900-26-074421","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cadrenal Therapeutics entered into a securities purchase agreement on June 30, 2026, for a private placement of pre-funded warrants, Series C-1 warrants, and Series C-2 warrants to purchase up to 2.88 million shares of common stock at a combined price of $3.1249 per unit, generating $3.0 million in gross proceeds. This is a classic dilutive equity issuance under Section 4(a)(2) of the Securities Act, structured as an unregistered private placement with warrant components. The filing explicitly notes the securities were not registered and references registration rights obligations, typical of PIPE-like transactions at small-cap biopharmaceutical companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:20:00.539458+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13472,"accession_number":"0001213900-26-074421","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cadrenal Therapeutics disclosed an unregistered private placement of 960,000 shares of common stock (or pre-funded warrants), series C-1 and C-2 warrants, and placement agent warrants under Section 4(a)(2) and Regulation D exemptions. The offering raised $3 million upfront with up to $5.8 million in potential additional proceeds from warrant exercises, extending the company's cash runway into Q1 2027 (or H2 2027 if warrants are exercised). This is a classic dilutive equity issuance by a biopharmaceutical company raising capital to fund operations and advance its pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:20:00.539458+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13473,"accession_number":"0001213900-26-074421","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cadrenal Therapeutics announced the pricing of a private placement of 960,000 shares of common stock (or pre-funded warrants) plus series C-1 and C-2 warrants for $3.125 per share, generating $3 million upfront with up to $5.8 million in potential additional proceeds. This is an unregistered equity issuance under Section 4(a)(2) and Regulation D, structured as a PIPE-like transaction with warrants. The press release explicitly states the securities \"have not been registered under the Act\" and notes the company will file registration statements for resale. For a biopharmaceutical company with limited cash runway (extending only to Q1 2027 without warrant exercise), this dilutive capital raise is material to investors assessing the company's financial position and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:20:00.539458+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13471,"accession_number":"0001213900-26-074421","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cadrenal Therapeutics entered into a securities purchase agreement on June 30, 2026, for a private placement of pre-funded warrants, Series C-1 warrants, and Series C-2 warrants to purchase up to 2.88 million shares of common stock at a combined price of $3.1249 per unit, generating $3.0 million in gross proceeds. This is a classic dilutive equity issuance under Section 4(a)(2) of the Securities Act, structured as an unregistered private placement with warrant components. The filing explicitly notes the securities were not registered and references registration rights obligations, typical of PIPE-like transactions at small-cap biopharmaceutical companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:20:00.539458+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-07-01"},{"id":13472,"accession_number":"0001213900-26-074421","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cadrenal Therapeutics disclosed an unregistered private placement of 960,000 shares of common stock (or pre-funded warrants), series C-1 and C-2 warrants, and placement agent warrants under Section 4(a)(2) and Regulation D exemptions. The offering raised $3 million upfront with up to $5.8 million in potential additional proceeds from warrant exercises, extending the company's cash runway into Q1 2027 (or H2 2027 if warrants are exercised). This is a classic dilutive equity issuance by a biopharmaceutical company raising capital to fund operations and advance its pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:20:00.539458+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-07-01"},{"id":13473,"accession_number":"0001213900-26-074421","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cadrenal Therapeutics announced the pricing of a private placement of 960,000 shares of common stock (or pre-funded warrants) plus series C-1 and C-2 warrants for $3.125 per share, generating $3 million upfront with up to $5.8 million in potential additional proceeds. This is an unregistered equity issuance under Section 4(a)(2) and Regulation D, structured as a PIPE-like transaction with warrants. The press release explicitly states the securities \"have not been registered under the Act\" and notes the company will file registration statements for resale. For a biopharmaceutical company with limited cash runway (extending only to Q1 2027 without warrant exercise), this dilutive capital raise is material to investors assessing the company's financial position and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:20:00.539458+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-07-01"}]}